85666-17-7
Chemical Structure
Furegrelate sodium
Synonym(s): U-63557A
- CAS No.: 85666-17-7
- Formula:C15H10NNaO3
- Molecular Weight:275.23
IUPAC Name: sodium 5-(pyridin-3-ylmethyl)benzofuran-2-carboxylate
InChIKey: XBTIPIZROJAKOJ-UHFFFAOYSA-M
SMILES: O=C(C1=CC2=CC(CC3=CC=CN=C3)=CC=C2O1)O[Na]
Biological Activity: Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Furegrelate sodium | 99.69% | Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Furegrelate sodium (Standard) | ≥98% | Furegrelate (sodium) (Standard) is the analytical standard of Furegrelate (sodium). This product is intended for research and analytical applications. Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Gorman RR, et al. Inhibition of platelet thromboxane A2 synthase activity by sodium 5-(3'-pyridinylmethyl)benzofuran-2-carboxylate. Prostaglandins. 1983 Aug;26(2):325-42. [Content Brief]
- [2]. Hirenallur-S DK, et al. Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets. Pulm Circ. 2012 Apr-Jun;2(2):193-200. [Content Brief]